<DOC>
	<DOCNO>NCT00002376</DOCNO>
	<brief_summary>To evaluate , HIV-infected patient whose baseline CD4 count 300 750 cells/mm3 , whether antiretroviral treatment regimen base upon clinical evaluation CD4 count plus HIV RNA viral load effective treatment regimen base upon clinical evaluation CD4 count without use HIV RNA viral load information . To assess relative utility viral load test determine therapeutic choice surrogate marker CD4 cell count 48 week therapy . It hypothesize among HIV-infected patient whose baseline CD4 count range 300 750 cells/mm3 , patient incorporate initial periodic viral RNA measurement therapeutic decision higher CD4 count 48 week patient whose therapeutic decision incorporate initial periodic viral RNA measurement .</brief_summary>
	<brief_title>The Effectiveness HIV RNA Viral Load Testing Determining Treatment Type HIV-Infected Patients</brief_title>
	<detailed_description>It hypothesize among HIV-infected patient whose baseline CD4 count range 300 750 cells/mm3 , patient incorporate initial periodic viral RNA measurement therapeutic decision higher CD4 count 48 week patient whose therapeutic decision incorporate initial periodic viral RNA measurement . Approximately 540 patient stratified basis baseline CD4 count randomize one two treatment group : 1. viral RNA treatment group 2. non viral RNA treatment group . Treatment modification base upon CD4 count , viral RNA level ( group 1 ) clinical evaluation . Patients receive one three antiretroviral treatment : 1 . No antiretroviral therapy . 2 . Double reverse transcriptase inhibitor ( RTI ) therapy consist two therapy combination : didanosine ( ddI ) , lamivudine ( 3TC ) , stavudine ( d4T ) zidovudine ( ZDV ) , base upon treat physician 's judgment . The preferred combination ZDV + 3TC , d4T + 3TC ddI + d4T . 3 . Triple antiretroviral therapy consist double antiretroviral therapy plus indinavir . Treatment decision base upon standardized algorithm follow : CD4 count 500-750 + viral RNA &lt; 10,000 : Group 1 : No retroviral therapy . Group 2 : No retroviral therapy . CD4 count 500-750 + viral RNA &gt; = 10,000 : Group 1 : Triple therapy . Group 2 : No retroviral therapy . CD4 count 300-499 + viral RNA &lt; 10,000 : Group 1 : Double retroviral therapy . Group 2 : Double retroviral therapy . CD4 count 300-499 + viral RNA &gt; = 10,000 : Group 1 : Triple therapy . Group 2 : Double retroviral therapy . CD4 count 200-299 + viral RNA &lt; 10,000 : Group 1 : Maintain retroviral therapy unless : CD4 count decrease 25-49 % within 24 week count fall range 300-499 case retroviral therapy change , CD4 count decrease &gt; = 50 % within 48 week therapy time CD4 count fell within range 300-499 case triple therapy initiate , AIDS-defining illness case triple therapy initiate . Group 2 : Same Group 1 . CD4 count 200-299 + viral RNA &gt; = 10,000 : Group 1 : Triple therapy . Group 2 : Maintain retroviral therapy unless : CD4 count decrease 25-49 % within 24 week count fall range 300-499 case retroviral therapy change , CD4 count decrease &gt; = 50 % within 48 week therapy time CD4 count fell within range 300-499 case triple therapy initiate , AIDS-defining illness case triple therapy initiate . CD4 count &lt; 200 : Group 1 : Triple therapy . Group 2 : Triple therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : CD4 count &gt; = 300 &lt; = 750 cells/mm3 . Exclusion Criteria Prior Medication : Excluded : Prior protease inhibitor therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>